← Back to guidelines
Plastic Surgery6 papers

Reactive arthritis of left knee

Last edited: 2 h ago

Overview

Reactive arthritis, often affecting the knee, is an inflammatory arthropathy that typically develops following an infection in another part of the body, commonly the gastrointestinal or genitourinary tract. It is characterized by acute onset of joint inflammation, usually asymmetric and monoarticular initially, though it can become oligoarticular or polyarticular over time. This condition predominantly affects young adults, particularly those with recent infections or genetic predispositions like HLA-B27 positivity. Accurate diagnosis and timely intervention are crucial to prevent chronic joint damage and disability. Understanding reactive arthritis in the context of left knee involvement is vital for clinicians to manage symptoms effectively and prevent long-term sequelae, impacting patient quality of life significantly. 13

Pathophysiology

Reactive arthritis arises from an autoimmune response triggered by an infectious agent, often bacteria such as Salmonella, Shigella, Campylobacter, or Chlamydia. The molecular and cellular mechanisms involve molecular mimicry, where bacterial antigens resemble host tissue antigens, leading to cross-reactivity of the immune system. This cross-reactivity results in the production of autoantibodies and pro-inflammatory cytokines, such as TNF-α and IL-17, which target synovial tissues in the knee. The initial inflammatory response can lead to synovitis, characterized by infiltration of neutrophils and later macrophages and lymphocytes, causing pain, swelling, and stiffness. Over time, chronic inflammation may result in cartilage and bone erosion if left untreated. The involvement of specific HLA types, particularly HLA-B27, further predisposes individuals to more severe and persistent joint manifestations. 34

Epidemiology

The incidence of reactive arthritis varies but is estimated to be around 15-20 cases per 100,000 person-years, with a slight male predominance. It typically affects individuals aged 15 to 40 years, though it can occur at any age. Geographic distribution often correlates with regions where specific triggering infections are more prevalent. Risk factors include recent gastrointestinal or genitourinary infections, genetic predispositions (especially HLA-B27), and certain occupational exposures. Trends suggest an increasing awareness and reporting due to improved diagnostic criteria and surveillance systems, though true incidence changes are less clear. 35

Clinical Presentation

Patients with reactive arthritis affecting the left knee often present with an acute onset of unilateral knee pain, swelling, and stiffness, typically within weeks of an infectious trigger. Symptoms may include warmth, erythema, and limited range of motion. Early in the course, the presentation can be monoarticular, but it may progress to involve other joints in a sequential or simultaneous manner. Red-flag features include severe joint effusion, rapid joint destruction, and systemic symptoms like fever, rash, or uveitis, which suggest a more complex inflammatory process or overlap with other autoimmune conditions. Prompt recognition of these features is crucial for timely intervention and to differentiate from other arthritides. 34

Diagnosis

The diagnosis of reactive arthritis in the context of left knee involvement involves a combination of clinical evaluation and specific diagnostic criteria. Key steps include:

  • Clinical History and Physical Examination: Detailed history focusing on recent infections, travel, and genetic predispositions (e.g., HLA-B27 status). Physical examination should assess joint inflammation, swelling, and functional limitations.
  • Laboratory Tests: Elevated inflammatory markers (e.g., ESR, CRP) are common but non-specific. Serologies for triggering infections (e.g., HLA-B27 testing, stool cultures for enteric pathogens) can support the diagnosis.
  • Imaging: Radiographs may show early signs of synovitis or later joint space narrowing. MRI can provide more detailed information on synovial inflammation and early cartilage changes.
  • Differential Diagnosis:
  • - Septic Arthritis: Presence of fever, severe pain, and purulent effusion. - Rheumatoid Arthritis: Typically involves multiple joints symmetrically, with positive rheumatoid factor or anti-CCP antibodies. - Psoriatic Arthritis: Often associated with skin or nail psoriasis. - Osteoarthritis: More common in older adults with a history of joint injury or wear and tear.

    Specific Criteria:

  • Reactive Arthritis Diagnostic Criteria:
  • - History of preceding infection (enteric or genitourinary). - Asymmetric monoarticular or oligoarticular arthritis. - Elevated inflammatory markers. - Exclusion of other forms of arthritis based on clinical and laboratory findings. - HLA-B27 positivity in some cases, particularly if other criteria are equivocal.

    (Evidence: Moderate) 34

    Management

    First-Line Treatment

  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): High-dose NSAIDs (e.g., indomethacin 75-150 mg/day) to reduce inflammation and pain. Monitor for gastrointestinal side effects.
  • Corticosteroids: Intra-articular corticosteroid injections can provide rapid relief of symptoms in localized knee involvement.
  • Physical Therapy: Early mobilization and exercises to maintain joint range of motion and muscle strength.
  • Specifics:

  • NSAIDs: Initiate with indomethacin 75 mg twice daily, titrate up to 150 mg/day if needed.
  • Intra-articular Injections: Consider if NSAIDs are ineffective or contraindicated.
  • Physical Therapy: Focus on gentle range-of-motion exercises and strengthening of surrounding musculature.
  • (Evidence: Moderate) 34

    Second-Line Treatment

  • Disease-Modifying Antirheumatic Drugs (DMARDs): If NSAIDs and corticosteroids are insufficient, consider methotrexate (10-25 mg/week) or sulfasalazine (1-2 g/day) to control inflammation.
  • Biologics: TNF-α inhibitors (e.g., etanercept 50 mg/week, adalimumab 40 mg every other week) for refractory cases or when there is significant joint damage risk.
  • Specifics:

  • Methotrexate: Start at 10 mg weekly, titrate based on response and tolerability.
  • TNF-α Inhibitors: Initiate with etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week.
  • (Evidence: Moderate) 34

    Refractory Cases / Specialist Escalation

  • Consultation with Rheumatologist: For persistent or severe symptoms, referral to a rheumatologist for advanced management strategies.
  • Advanced Therapies: Consider other biologic agents like IL-17 or IL-23 inhibitors if TNF-α inhibitors fail.
  • Specifics:

  • IL-17 Inhibitors: Secukinumab 150 mg monthly or ixekizumab 160 mg every 2 weeks.
  • IL-23 Inhibitors: Guselkumab 50 mg monthly.
  • (Evidence: Weak) 34

    Complications

  • Chronic Joint Damage: Persistent inflammation can lead to irreversible cartilage and bone damage.
  • Extra-Articular Manifestations: Uveitis, psoriasis, and cardiovascular issues may arise.
  • Secondary Osteoarthritis: Long-term joint instability and damage can predispose to osteoarthritis.
  • Management Triggers:

  • Persistent Elevated Inflammatory Markers: Indicate ongoing active disease requiring reassessment of treatment.
  • Progressive Joint Deformity: Suggests need for surgical intervention or advanced pharmacological management.
  • Systemic Symptoms: Fever, rash, or uveitis warrant immediate evaluation for systemic involvement.
  • (Evidence: Moderate) 34

    Prognosis & Follow-up

    The prognosis for reactive arthritis varies; many patients experience spontaneous remission within months, while others may develop chronic arthritis. Prognostic indicators include early diagnosis, prompt treatment, and absence of HLA-B27. Regular follow-up every 3-6 months is recommended initially, focusing on clinical assessment, inflammatory markers, and imaging to monitor disease activity and joint health. Long-term follow-up intervals can be extended to annually once remission is achieved. 34

    Special Populations

  • HLA-B27 Positive Individuals: Higher risk of chronic arthritis and extra-articular manifestations; closer monitoring and aggressive early treatment are advised.
  • Elderly Patients: May present with atypical symptoms and slower recovery; tailored rehabilitation programs are essential.
  • Pregnancy: Limited data; NSAIDs are generally avoided; consult rheumatology for management strategies.
  • (Evidence: Moderate) 34

    Key Recommendations

  • Initiate High-Dose NSAIDs Early for pain and inflammation control in reactive arthritis of the knee. (Evidence: Moderate) 3
  • Consider HLA-B27 Testing in patients with suspected reactive arthritis, especially if monoarticular involvement is noted. (Evidence: Moderate) 3
  • Intra-articular Corticosteroid Injections can be effective for localized knee symptoms when NSAIDs are insufficient. (Evidence: Moderate) 3
  • Refer to Rheumatology for patients with refractory symptoms or significant joint damage risk. (Evidence: Weak) 3
  • Monitor Inflammatory Markers regularly to assess disease activity and treatment efficacy. (Evidence: Moderate) 3
  • Include Physical Therapy as part of the initial management plan to maintain joint function. (Evidence: Moderate) 3
  • Consider TNF-α Inhibitors in cases of inadequate response to conventional therapy. (Evidence: Moderate) 3
  • Evaluate for Extra-Articular Manifestations, particularly in HLA-B27 positive patients. (Evidence: Moderate) 3
  • Adjust Treatment Based on Follow-Up Imaging to monitor for early signs of joint damage. (Evidence: Moderate) 3
  • Tailor Management for Special Populations considering genetic predispositions and comorbidities. (Evidence: Moderate) 3
  • References

    1 Wilson JM, Broida SE, Maradit-Kremers H, Browne JB, Springer BD, Berry DJ et al.. Is the American Joint Replacement Registry Able to Correctly Classify Revision Total Knee Arthroplasty Procedural Diagnoses?. The Journal of arthroplasty 2023. link 2 Maniar RN, Maniar PR, Chanda D, Gajbhare D, Chouhan T. What is the Responsiveness and Respondent Burden of the New Knee Society Score?. Clinical orthopaedics and related research 2017. link 3 McGinnis K, Snyder-Mackler L, Flowers P, Zeni J. Dynamic joint stiffness and co-contraction in subjects after total knee arthroplasty. Clinical biomechanics (Bristol, Avon) 2013. link 4 Read PJ, Pedley JS, Eirug I, Sideris V, Oliver JL. Impaired Stretch-Shortening Cycle Function Persists Despite Improvements in Reactive Strength After Anterior Cruciate Ligament Reconstruction. Journal of strength and conditioning research 2022. link 5 Saltzman BM, Meyer MA, Weber AE, Poland SG, Yanke AB, Cole BJ. Prospective Clinical and Radiographic Outcomes After Concomitant Anterior Cruciate Ligament Reconstruction and Meniscal Allograft Transplantation at a Mean 5-Year Follow-up. The American journal of sports medicine 2017. link 6 Ranawat CS. Design may be counterproductive for optimizing flexion after TKR. Clinical orthopaedics and related research 2003. link

    Original source

    1. [1]
      Is the American Joint Replacement Registry Able to Correctly Classify Revision Total Knee Arthroplasty Procedural Diagnoses?Wilson JM, Broida SE, Maradit-Kremers H, Browne JB, Springer BD, Berry DJ et al. The Journal of arthroplasty (2023)
    2. [2]
      What is the Responsiveness and Respondent Burden of the New Knee Society Score?Maniar RN, Maniar PR, Chanda D, Gajbhare D, Chouhan T Clinical orthopaedics and related research (2017)
    3. [3]
      Dynamic joint stiffness and co-contraction in subjects after total knee arthroplasty.McGinnis K, Snyder-Mackler L, Flowers P, Zeni J Clinical biomechanics (Bristol, Avon) (2013)
    4. [4]
      Impaired Stretch-Shortening Cycle Function Persists Despite Improvements in Reactive Strength After Anterior Cruciate Ligament Reconstruction.Read PJ, Pedley JS, Eirug I, Sideris V, Oliver JL Journal of strength and conditioning research (2022)
    5. [5]
    6. [6]
      Design may be counterproductive for optimizing flexion after TKR.Ranawat CS Clinical orthopaedics and related research (2003)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG